Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Hematology, Transfusion and Cell Therapy is Scopus-indexed (Q3, CiteScore 2.2), WoS ESCI, DOAJ. Published by Elsevier Editora Ltda.
Checked against the index lists dated .
ISSN 2531-1379Verify ISSN ↗2531-1387Verify ISSN ↗
Publisher: Elsevier Editora Ltda
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Hematology | 89 / 151 | 41st | Q3 |
| Immunology and Allergy | 177 / 234 | 24th | Q4 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2018–present, best quartile Q3, CiteScore 2.2.
Hematology, Transfusion and Cell Therapy is Q3 in Hematology (rank 89 of 151) and Q4 in Immunology and Allergy (rank 177 of 234), by CiteScore 2025.
Hematology, Transfusion and Cell Therapy is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.2, which places it in quartile Q3 at the 41st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.370, quartile Q3, with an H-index of 38.
No article processing charge is recorded for it (source: OpenAlex). Confirm on the journal's own website, since some journals charge for extras such as colour figures.
Hematology, Transfusion and Cell Therapy is published by Elsevier Editora Ltda. Its print ISSN is 2531-1379 and its online ISSN is 2531-1387.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Hematology, Transfusion and Cell Therapy has an h-index of 31 and a 2-year mean of 0.12 citations per paper (OpenAlex). Its Scopus CiteScore is 2.2, quartile Q3. On 2-year citations it ranks #134 of 148 Scopus journals in Hematology.
Hematology, Transfusion and Cell Therapy published 2,397 papers in 2025; its busiest recent year was 2024 with 2,515. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2026), authors are most often from Brazil (54.9%), India (10.4%) and United States (3.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.2 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.